Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 14/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12099897 | 0.83 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2ACRHBPCRHR2 | |
| SCHEMBL6854664 | 0.72 | ALDH1A1 (0.33) | ALDH1A1MEN1KMT2ACRHBPCRHR2 | |
| SCHEMBL1304464 | 0.69 | KIF11 (0.35) | KIF11SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL12468591 | 0.65 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2ACRHBPCRHR2 | |
| SCHEMBL8559220 | 0.61 | PPARG (0.53) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8559217 | 0.61 | PPARG (0.53) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL28935966 | 0.60 | SLC1A1 (0.41) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL8563110 | 0.60 | SMN1; SMN2 (0.43) | KIF11 | |
| SCHEMBL8563107 | 0.60 | SMN1; SMN2 (0.43) | KIF11 | |
| Hydrochloric Acid SCHEMBL28963262 | 0.59 | SLC1A1 (0.40) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048896-B2 | Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors | Cell Viable Corporation (US) | 2011-11-01 | — | — | US | claimed |
| US-8048896-B2 | Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors | Cell Viable Corporation (US) | 2011-11-01 | — | — | US | disclosed |
| US-20080076804-A1 | METHODS FOR INHIBITING AND BREAKING AGE COMPLEX FORMATION | Cell Viable Corporation | 2008-03-27 | — | — | US | disclosed |